NuLife Sciences
The Future of Transplants

Investor Relations Contact
Ted Haberfield
President – MZ North America
Direct: 760-755-2716
thaberfield@mzgroup.us
www.mzgroup.us

NuLife Sciences, Inc. (OTCQB: NULF) is a biomedical company focused on advancing human organ transplant technology and medical research. NuLife has a patent protected unique proprietary method ("NuLife Technique") that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs. With a massive need and market for organ transplants, and over 123K candidates waiting for an organ in the U.S. alone, NuLife's versatile technique is suitable for a variety of clinical indications. The Company has completed discovery phase for its technique, and is now entering a Preclinical phase involving animal experiments on its pathway to commercialization. NuLife Sciences will also provide an online marketplace and community to assist in creating jobs and enable entrepreneurs and service providers to offer health related products and services within local markets.

Investment Highlights

- Novel, patented technique with the potential to transform the transplantation market
- Massive need and market for organ transplants with over 123K candidates waiting for an organ in the US alone
- Versatile technique suitable for a variety of clinical indications
- High entry barrier for competition
- Comprehensive patent and IP protections in place
- Strong executive team with surgical research team having extensive academic background and clinical experience in transplantation

The NuLife Technique

- Developed through 15 years of committed research
- The result has been multiple breakthroughs in hematopoietic research and transplant techniques
- The goal of the research was to address the issues of organ compatibility and the need for anti -rejection drugs in the donor
- Pilot Studies:
  - 1st surgery – 3 years ago - 4 surgeries in total (2-3 animals per surgery)

Transplantation Today

In the U.S. ~31,000 organ transplants occur every year but there are ~123,000 people on the candidate waiting list for a transplant.

Why?

Organ availability

- 22 people die each day in America waiting for transplants that can't take place because of the shortage of donated organs

High costs and problems of anti-rejection drugs

- Average costs of the immunosuppressive drugs is approximately $17,000 per year (Medicare only covers the first three years)
- These drugs also cause increased infection and cancer rates - ultimately destroy the organs

Initial Target Market

- Most common transplant – about 18,000 in 2015
- Most patients spend years on dialysis while waiting
- Many never receive the actual transplant
- All current transplant patients require anti-rejection drugs

*Facts and statistics cited by the U.S. Department of Health & Human Services Organ Procurement and Transplantation Network (OPTN), the Scientific Registry of Transplant Recipients (SRTR) Annual Report, and www.organdonor.gov.

Donation Breakdown by Year



Organ Donation by Type

Percentage breakdown of the 30,973 transplants performed in the US in 2015



The NuLife Technique - Full Process in Stages



1. Removing kidneys from one patient (swine anatomy and physiology are very similar to humans)
2. Proceeding with decellularization process
3. Creation of a kidney 'scaffold', upon which a new kidney specific to the recipient can be rebuilt
4. The kidney scaffold is populated/injected by bone marrow (immature) cells from the recipient, allowing the stem cells to differentiate into mature kidney cells
5. Growth of a kidney that is genetically identical to the recipient
6. The processed blood is given to the recipient to aid the recellularization process before and after the organ is implanted.

The process allows for creation of organs that required no additional immunosuppression, ultimately prolonging kidney longevity, and expands the population of usable kidneys.

Impact on the Transplant System

Donor organs are matched via national computer registry called the National Organ Procurement and Transplantation Network (OPTN) – Organ Procurement Organization (OPO) has offices in all 50 states and serve as gatekeepers



	Traditional	NuLife
Costs	• Anti-rejection drugs ($17K/yr) • Dialysis while waiting ($85K/yr)	• No anti-rejection drugs • Little to no dialysis
Quality of Life	• Anti-rejection drugs severely diminish quality	• No anti-rejection drugs
Mortality Rates	• 22 people per day die waiting	• Time to transplant is minimal

Pathway to Commercialization

Technology	Discovery	Preclinical	Clinical
The NuLife Technique • Developed over 15 years • Applied to wound healing	**Completed** • Patent applications filed • Patents issued in 2015	**Animal experiments** 1 experiment per month with 3 animals for +/- 12 experiments **In collaboration with:** FIU Florida International University; NOVA Southeastern University • Preliminary animal studies conducted • Next studies planned for 1H17	✓ Complete appropriate documentation ✓ Expand advisory board ✓ Meet with FDA to propose clinical pathway in 2017

Data derived from clinical trial will be submitted to FDA, IRBs and other regulatory bodies to determine final pathway to commercialization

Management

James Gandy, Founder - A wound care specialist, medical researcher, entrepreneur and patent developer. He is currently the Founder and President of NuLife, formed to formalize ongoing research that has the potential to save countless lives. James has spent years advancing a number of medical breakthroughs- from wound care treatment to autoimmune disease. The more he learned about the human body, the more eager he was to continue with his research. He made the bold decision to leave American Medical University in 2006 to dedicate all of his time and attention to research in the area of cytokines and growth factors, and their use in the human body for tissue damage repair. He has applied this knowledge and focused it on two main areas. One of those is the effects of cytokines and the other is in organ transplant.

John Hollister, CEO - Executive with over 25 years of leadership experience in large pharmaceuticals, biotech (established and start-up), and medical device (software and diagnostics). Extensive experience in all aspects of commercialization in the healthcare industry. In particular, strong background in oncology, hematology, vaccines, and diabetes. John was previously CEO of Nemus Bioscience and served as a strategic consultant working with early stage healthcare companies. He served as SVP of Marketing for Tethys Bioscience, a diabetes diagnostic company and CEO of EEG Spectrum International, a private device company. He served in a series of Commercial positions, including the Global Commercial Leader in Oncology at Amgen where he led multiple teams in developing oncology assets from preclinical to phase IV. Prior to Amgen, Mr. Hollister started his pharmaceutical career at SmithKline Beecham. Mr. Hollister has his BA in Economics from Stanford University and his MBA from the Drucker Center at the Claremont Graduate University.

Fred Luke, President - Fred has over 40 years of experience in providing operational and financial consulting services. He has assisted companies with entity formation and business planning, multi-national mergers and acquisitions, reverse mergers, corporate finance, debt restructuring, and arranging conventional debt and equity financing. Since 1970, Fred has provided consulting and management services and has served as a director, chairman, chief accounting officer, president and chief executive officer of over 100 public and privately-held companies. He has worked in Asia, Europe, Canada, and North Africa. Fred's clients have been active in various business segments, domestic banking, the creation of domestic and foreign tax shelters, telecommunications, commercial airlines, real estate, domestic film financing, clothing and food manufacturing, casino gaming and hotel operations, oil and gas exploration, oil and gas transportation and refining, alternative energy, equipment leasing, network marketing, and international finance.